- Previous
- Next
02 May 2026
Moving onto Solids
CAR T therapy – where the T cells of a cancer patient's immune system are genetically engineered to recognise and kill tumour cells – is transforming the treatment of 'liquid' cancers (such as leukaemia, lymphoma and myeloma). Its application for solid tumours, however, hasn't been straightforward. But that may be set to change as a fitting target for CAR T therapy against solid cancer has now been identified – a molecule called urokinase plasminogen activator receptor
Image made using Leica Microsystems Cell DIVE multiplex imaging
Read the published research article here
Written by
Search The Archive
Submit An Image
Like us on Facebook
Follow on Twitter
Follow on Tumblr
Follow on Instagram
What is BPoD?
BPoD stands for Biomedical Picture of the Day. Managed by the MRC Laboratory of Medical Sciences until Jul 2023, it is now run independently by a dedicated team of scientists and writers. The website aims to engage everyone, young and old, in the wonders of biology, and its influence on medicine. The ever-growing archive of more than 4000 research images documents over a decade of progress. Explore the collection and see what you discover. Images are kindly provided for inclusion on this website through the generosity of scientists across the globe.
BPoD is also available in Catalan at www.bpod.cat with translations by the University of Valencia.